Recent studies have shown that pharmacologic restoration of PP2A tumor suppressor activity by PP2A-activating drugs (PADs; for example, forskolin, FTY720) effectively antagonizes cancer development and progression [60]. This evidence concerns the gene PTPA and cancer.